GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc filed a Form 6-K reporting transaction notifications. The filing lists share transactions with an ISIN GB00BN7SWP63 at a price of 3.0300 and multiple entries for ISIN US37733W2044 at a price of $40.7387. The document repeats the US ISIN and price across several lines and provides an aggregated section header, but it does not disclose volumes, the parties to the transactions, transaction types, or any explanatory context. The filing is dated September 22, 2025.
GSK plc reported share repurchases under its ongoing buyback programme. On 18 September 2025 the Company, through Merrill Lynch International, purchased 15,858 ordinary shares at prices between 1,471.00p and 1,480.00p, with an aggregated per-share reference of 1,476.54p. Since the non-discretionary agreement began on 4 June 2025 the Company has purchased 29,330,461 ordinary shares. After these transactions GSK holds 247,464,844 shares in treasury and has 4,067,938,124 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,067,938,124 and the percentage of voting rights attributable to treasury shares is stated as 6.08%.
GSK plc repurchased 209,886 ordinary shares on 17 September 2025 through Merrill Lynch International under its ongoing buyback programme, at prices ranging from 1,461.50p to 1,478.50p, with an average price reported as 1,471.87p. The purchased shares will be held as treasury shares.
Since the non-discretionary agreement with the broker on 4 June 2025 the company has acquired 29,314,603 ordinary shares. After this trade GSK holds 247,448,986 shares in treasury and has 4,067,953,982 ordinary shares in issue (excluding treasury), representing total voting rights of 4,067,953,982 and 6.08% of voting rights attributable to treasury shares.
GSK announced a five-year, $30 billion investment plan in the United States to expand research, development and supply chain infrastructure. The announcement includes a $1.2 billion package for advanced manufacturing, AI and digital capabilities that will create hundreds of highly skilled U.S. jobs and build a next-generation biologics "flex" factory at Upper Merion, Pennsylvania, with construction planned to begin in 2026. GSK said the wider $30 billion commitment will fund capital projects across its U.S. supply chain, boost R&D drug discovery and clinical trial activity, and increase the U.S. share of its global clinical studies. The filing notes GSK has added roughly $2 billion in U.S. manufacturing investments over the last 12 months, including an $800 million Marietta, Pennsylvania facility started in October 2024, and that its global supply chain delivered 1.7 billion packs of medicines and over 400 million vaccine doses last year.
GSK plc announced that, acting through Merrill Lynch International, it repurchased 210,377 ordinary shares on 16 September 2025 at prices between 1,462.00p and 1,478.00p per share, with an aggregated average shown as 1,468.98p. These shares will be held as treasury stock as part of the buyback programme announced 4 June 2025. Since 4 June 2025 the company has repurchased 29,104,717 ordinary shares. After this trade GSK holds 247,239,100 shares in treasury and has 4,068,163,868 ordinary shares in issue (excluding treasury), giving total voting rights of 4,068,163,868 and treasury-held voting rights of 6.08%.
GSK plc reported a purchase of ordinary shares under its ongoing buyback programme. On 15 September 2025 the Company, acting through Merrill Lynch International, purchased 253,331 ordinary shares at prices ranging up to 1,505.50p, with an aggregated weighted lowest/highest/average price line reported as 1,476.00p / 1,505.50p / 1,482.92p on that date. Since the non-discretionary agreement with the Broker dated 4 June 2025, GSK has purchased 28,894,340 ordinary shares in total. Following the 15 September purchase the Company holds 247,028,723 shares in treasury and has 4,068,374,245 ordinary shares in issue (excluding treasury), giving total voting rights of 4,068,374,245 and treasury shares representing 6.07% of voting rights.
GSK plc reports on 12 September 2025 that, acting through Merrill Lynch International, it purchased 203,447 ordinary shares at an average price of 1,512.69p per share as part of its ongoing buyback programme under a non-discretionary broker agreement dated 4 June 2025. Since 4 June 2025 the company has repurchased 28,641,009 ordinary shares. Following the transaction GSK will hold 246,775,392 shares in treasury and will have 4,068,627,576 ordinary shares in issue (excluding treasury). Total voting rights are 4,068,627,576 and treasury shares represent 6.07% of voting rights.
GSK plc reported purchases of its ordinary shares on 11 September 2025 under an existing buyback programme. Acting through Merrill Lynch International, the Company purchased 205,355 ordinary shares at prices ranging from 1,494.50p to 1,518.50p, resulting in an average price shown as 1,509.04p for the aggregated trade line. The purchased shares will be held as treasury shares and form part of the non-discretionary agreement with the broker entered into on 4 June 2025. Since 4 June 2025 the Company has acquired 28,437,562 ordinary shares under the programme. After this transaction GSK will hold 246,571,945 shares in treasury and have 4,068,829,782 ordinary shares in issue (excluding treasury), with total voting rights of 4,068,829,782 and 6.06% of voting rights attributable to treasury shares.
GSK plc reports a share repurchase carried out on 10 September 2025 under its ongoing buyback programme executed by Merrill Lynch International. On that date the Company purchased 213,147 ordinary shares at prices ranging between 1,480.50p and 1,500.00p per share; the aggregated lowest and highest prices reported are 1,480.50p and 1,500.00p respectively.
Since the non-discretionary agreement with the Broker on 4 June 2025, GSK has bought 28,232,207 ordinary shares. Following the latest purchases the Company holds 246,366,590 treasury shares and has 4,069,035,137 ordinary shares in issue (excluding treasury), giving a total number of voting rights of 4,069,035,137 and treasury-held voting rights of 6.05%.
GSK plc reported small share purchases by several senior executives under its Share Reward Plan. On 2025-09-09, CEO Emma Walmsley acquired 18 ordinary shares, split between partnership and matching shares, at £14.8574 per share on the London Stock Exchange. CFO Julie Brown acquired 16 ordinary shares on the same terms and date.
Additional participants included senior leaders such as the Group General Counsel, heads of corporate development, global supply chain, global affairs, ViiV Healthcare and global health, global communications, and the company secretary. Each of these executives acquired between 16 and 18 ordinary shares, also at £14.8574 per share through the plan.